MedTrace Logo

Longitudinal Follow-up of a Population Cohort in a French City With High SARS-CoV-2 Circulation, in Early 2020 [COVID-19]

NCT04644159 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2023-07-07

No results posted yet for this study

Summary

An initial retrospective epidemiological investigation was conducted in a city north of France after the diagnosis of the first case of COVID-19 on February 2020. Sero-epidemiological studies were conducted in this town by the Institut Pasteur in early 2020 among families, teachers and non-teaching staff of the high and elementary schools.

The goal of this new project is to better characterize the specific immunity generated by the infection within this community. The specific immune response to the SARS-CoV-2 virus will be followed for a period of 2 years from the initial circulation of the virus, within a large cohort of participants covering all age groups from 5 years-old onwards. The study will focus on systemic humoral and cell responses, immunity of the nasopharyngeal mucosa and the humoral response present in saliva. Follow-up of participants in this cohort and monitoring of the virus circulation within this community would help to determine the protective character against re-infection of the natural immunity generated by SARS-CoV-2.

Conditions

  • SARS (Severe Acute Respiratory Syndrome)
  • Covid19

Interventions

OTHER

Human biological samples

Blood , saliva, nasopharyngeal mucosa

Sponsors & Collaborators

  • Institut Pasteur

    lead INDUSTRY

Principal Investigators

  • Marie-Noëlle Ungeheuer, Dr · Institut Pasteur

Eligibility

Min Age
5 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-11-13
Primary Completion
2022-06-30
Completion
2023-07-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04644159 on ClinicalTrials.gov